Hospital Quironsalud Sagrado Corazon

Hospital Quironsalud Sagrado Corazon is conducting trials that explore innovative treatments for breast cancer, non‑small cell lung cancer, and metastatic castration‑resistant prostate cancer. The studies aim to improve survival and reduce disease progression through targeted therapies, immunotherapy combinations, and novel drug regimens.

• Hormone receptor‑positive breast cancer
• HER2‑positive metastatic breast cancer
• Triple‑negative breast cancer
• Non‑small cell lung cancer
• Metastatic castration‑resistant prostate cancer

These trials evaluate new agents such as antibody‑drug conjugates, CDK4/6 inhibitors, and PARP inhibitors to determine their effectiveness in extending patient outcomes.

Research at the site focuses on chronic autoimmune conditions including systemic lupus erythematosus and psoriatic arthritis. The goal is to test novel immunomodulators that can lower disease activity and improve quality of life for patients with severe systemic inflammation.

• Systemic lupus erythematosus
• Sjögren’s syndrome
• Psoriatic arthritis
• Cutaneous lupus erythematosus
• Autoimmune skin disorders

The studies assess agents such as selective S1P receptor modulators and IL‑23 inhibitors to achieve sustained remission.

The department is evaluating therapies for joint degeneration, notably erosive hand osteoarthritis and knee osteoarthritis. Trials aim to reduce pain, enhance mobility, and potentially modify disease progression with disease‑modifying osteoarthritis drugs and targeted biologics.

• Erosive hand osteoarthritis
• Knee synovitis and osteoarthritis
• Inflammatory osteoarthritis of the hands
• Joint pain management
• Functional improvement in osteoarthritis

Outcomes measured include pain intensity scales and functional scores to determine clinical benefit.

A specific study investigates the safety of an antacid medication for pregnant women experiencing heartburn and gastro‑esophageal reflux. The objective is to ensure maternal comfort while monitoring fetal and newborn health outcomes.

• Heartburn and gastro‑esophageal reflux disease
• Upper gastrointestinal symptoms in pregnancy
• Antacid safety profile

Researchers track both maternal adverse events and perinatal outcomes to guide clinical recommendations.

Trials targeting skin manifestations of autoimmune disease include evaluation of biologics for psoriasis and related arthritic involvement. The studies seek to reduce skin lesions and joint inflammation through IL‑23 and IL‑17 pathway inhibition.

• Psoriasis
• Psoriatic arthritis axial disease
• Cutaneous lupus erythematosus
• Skin inflammation in autoimmune disorders

Efficacy is measured by standardized skin scores and patient‑reported outcome instruments.

The research program also addresses oral manifestations of systemic autoimmunity, such as dryness and glandular dysfunction in Sjögren’s syndrome. The aim is to improve salivary flow and oral comfort using targeted therapies.

• Salivary gland dysfunction
• Oral dryness in Sjögren’s syndrome
• Oral mucosal lesions in lupus

Patient‑reported dryness scores and objective salivary measurements are the primary endpoints.

Several investigations focus on the underlying biology of immune regulation, including immune checkpoint inhibition and cytokine modulation. These mechanistic studies support the development of therapies that fine‑tune the immune response in cancer and autoimmunity.

• Cytokine inhibition
• B‑cell modulation
• T‑cell activation pathways
• Immune checkpoint blockade
• Autoimmune pathway targeting

Biomarker analyses and immune profiling are incorporated to link biological effects with clinical outcomes.